Key result
A non-invasive approach using serial assessment of AlloMap, GcfDNA testing, echocardiography, and CMR indices can guide the indication for endomyocardial biopsy in asymptomatic transplanted patients.
Why the study?
Can a non-invasive approach using biomarkers and advanced imaging effectively detect cardiac allograft rejection in cardiac transplant patients?
Can a non-invasive approach using biomarkers and advanced imaging effectively detect cardiac allograft rejection in cardiac transplant patients?
A multimodal non-invasive approach combining biomarkers and advanced imaging may reduce the need for routine endomyocardial biopsy in asymptomatic cardiac transplant recipients.
No takes yet. Share an insight, caveat, or question.
May support serial non-invasive surveillance to reduce EMB use in stable recipients; leaves open prospective validation of integrated algorithms.
Mavrogeni et al. (2017) conducted a review in Cardiac allograft rejection. Noninvasive diagnostic approaches (AlloMap, GcfDNA, echocardiography, CMR) vs. Endomyocardial biopsy (EMB) was evaluated. A non-invasive approach using serial assessment of AlloMap, GcfDNA testing, echocardiography, and CMR indices can guide the indication for endomyocardial biopsy in asymptomatic transplanted patients.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: